Last reviewed · How we verify
P2Y12 antagonist
At a glance
| Generic name | P2Y12 antagonist |
|---|---|
| Also known as | PLAVIX (clopidogrel), TICLID (ticlopidine), EFFIENT (prasugrel), BRILINTA (ticagrelor) |
| Sponsor | Boston Scientific Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (PHASE3)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants (PHASE1)
- Anti-inflammatory Therapy for Recurrent In-stent Restenosis (PHASE4)
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease (PHASE2)
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P2Y12 antagonist CI brief — competitive landscape report
- P2Y12 antagonist updates RSS · CI watch RSS
- Boston Scientific Corporation portfolio CI